Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

APPY 0.435
price chart
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Company Shares of Venaxis, Inc. Rally 7.53%
Shares of Venaxis, Inc. (NASDAQ:APPY) rose by 7.53% in the past week and 7.29% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 8.27% and the outperformance increases to 8.49% for the last 4 weeks.
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
Form 8-K Venaxis, Inc. For: Apr 07
These forward-looking statements are qualified by the cautionary statements contained in Venaxis' news releases and SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2014, which Venaxis filed on March 30, 2015.
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent ...
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Morning Market Losers  Benzinga
Venaxis, Inc. Price Target Update
Venaxis, Inc. shares have received a Mean Price Target of $0.75. According to the rating issued from 2 Wall Street Analysts, the High Price Target is seen at $1 while the Lower end of the Price Target is seen at $0.5.
Venaxis, Inc. Analyst Rating Update  The Daily Rover
Venaxis Business Update
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis.
Company Shares of Venaxis, Inc. Drops by -7.63%
Venaxis, Inc. (NASDAQ:APPY) has dropped 7.63% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 3.22% in the last 4 weeks.
Company Shares of Venaxis, Inc. Drops by -17.39%
Venaxis, Inc. (NASDAQ:APPY) has lost 17.39% during the past week and dropped 17.08% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 17.06%.
Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)
With news being very light on names that I cover over the past few weeks, I wanted to initiate a new name today: Venaxis (NASDAQ:APPY).